Dynamic Multiple Sclerosis Warrior, Mother, Yoga Instructor and Philanthropist Releases Raw and Inspiring Book in Time for MS Awareness Month
March 01, 2021 06:23 ET | Balboa Press
PHOENIX, March 01, 2021 (GLOBE NEWSWIRE) -- March is Multiple Sclerosis Awareness Month and in its honor, author and MS warrior Julie Blew has released the gripping account of her diagnosis and...
BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
January 07, 2021 14:15 ET | BioNTech SE
Collaborative study of BioNTech with TRON and the University Medical Center and Research Center for Immunotherapy at Johannes Gutenberg University of Mainz introduces novel non-inflammatory mRNA...
BioNTech veröffentlicht Daten zu neuartigem mRNA-Impfstoffansatz gegen Autoimmunkrankheiten in Science
January 07, 2021 14:15 ET | BioNTech SE
Gemeinsame Studie von BioNTech, TRON und der Universitätsmedizin sowie dem Forschungszentrum für Immuntherapie der Johannes Gutenberg-Universität Mainz untersucht neuartigen entzündungshemmenden...
AB Science will host a live webcast on December 17, 2020 on masitinib results in Alzheimer’s Disease
December 16, 2020 11:55 ET | AB Science
  AB SCIENCE WILL HOST A LIVE WEBCAST ON THURSDAY DECEMBER 17, 2020 ON MASITINIB RESULTS IN ALZHEIMER’S DISEASE Paris, December 16, 2020, 6pm CET AB Science SA (NYSE Euronext –...
AB Science tiendra une conférence virtuelle le 17 décembre 2020 sur les résultats du masitinib dans la maladie d'Alzheimer
December 16, 2020 11:55 ET | AB Science
AB SCIENCE TIENDRA UNE CONFERENCE VIRTUELLE SUR LES RESULTATS DU MASITINIB DANS LA MALADIE D’ALZHEIMER LE JEUDI 17 DECEMBRE 2020 Paris, 16 décembre 2020, 18h AB Science SA (NYSE Euronext -...
AB Science annonce que l'étude de phase 2B/3 évaluant le masitinib dans la maladie d'Alzheimer a atteint son critère d'évaluation principal
December 16, 2020 01:53 ET | AB Science
L'ÉTUDE DE PHASE 2B/3 ÉVALUANT LE MASITINIB DANS LA MALADIE D'ALZHEIMER A ATTEINT SON OBJECTIF PRINCIPAL LE MASITINIB A EU UN EFFET SIGNIFICATIF SUR LA COGNITION, MESURÉE AVEC L'ADAS-COG, ET SUR...
AB Science announces that Phase 2B/3 study evaluating oral in Alzheimer’s disease met its primary endpoint
December 16, 2020 01:53 ET | AB Science
PHASE 2B/3 STUDY EVALUATING MASITINIB IN ALZHEIMER’S DISEASE MET ITS PRIMARY ENDPOINT MASITINIB DEMONSTRATED SIGNIFICANT EFFECT ON BOTH COGNITION, MEASURED WITH ADAS-COG, AND DAILY ACTIVITY,...
La BEI soutient AB Science dans son programme de développement Covid-19
November 30, 2020 00:56 ET | AB Science
Paris, 30 novembre 2020, 7 heures   La BEI soutient AB Science dans son programme de développement Covid-19 Signature d’un contrat de financement de 15,0 millions d’euros pour soutenir le programme...
EIB supports AB Science in its COVID-19 development programme
November 30, 2020 00:56 ET | AB Science
Paris, 30 November 2020, 7am  EIB supports AB Science in its COVID-19 development programme Financing deal worth €15.0 million signed to support clinical development programme for masitinibMasitinib...
Zhittya Logo.jpg
Multiple Sclerosis: Is Therapeutic Angiogenesis a Treatment or Even a Possible Cure?
November 18, 2020 00:00 ET | Zhittya Genesis Medicine Inc
LAS VEGAS, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (Zhittya), a private company, announced that it will give a Webinar broadcast on its potential breakthrough therapy to...